Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
Xencor, Inc.
Akeso
University of Michigan Rogel Cancer Center
BerGenBio ASA
Sanofi
Memorial Sloan Kettering Cancer Center
Pfizer
Nektar Therapeutics
Regeneron Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
University of California, Davis
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Washington University School of Medicine
Nevada Cancer Institute
University Hospital Muenster
Eli Lilly and Company